Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:EARS

Auris Medical (EARS) Stock Price, News & Analysis

Auris Medical logo

About Auris Medical Stock (NASDAQ:EARS)

Advanced Chart

Key Stats

Today's Range
$0.30
$0.43
50-Day Range
$2.25
$3.27
52-Week Range
$0.73
$6.60
Volume
830,271 shs
Average Volume
3.10 million shs
Market Capitalization
$3.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through Switzerland and Australia geographical segments. Its product pipeline includes AM-125, AM-201, AM301, Sonsuvi, and Keyzilen. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.

Receive EARS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Auris Medical and its competitors with MarketBeat's FREE daily newsletter.

EARS Stock News Headlines

Trump’s Sending THIS Crypto Higher on Purpose
Discover the coin set to explode in 2025! Trump could trigger THIS crypto coin…
Envoy Medical receives FDA approval to initiate study for hearing device
See More Headlines

EARS Stock Analysis - Frequently Asked Questions

Auris Medical Holding Ltd. (NASDAQ:EARS) posted its earnings results on Thursday, May, 11th. The biotechnology company reported ($4.40) EPS for the quarter, missing the consensus estimate of ($2.80) by $1.60.

Auris Medical's stock reverse split before market open on Wednesday, May 1st 2019. The 1-20 reverse split was announced on Tuesday, April 30th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 30th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Auris Medical investors own include Helios and Matheson Analytics (HMNY), TransEnterix (TRXDW), Novavax (NVAX), OPKO Health (OPK), Anavex Life Sciences (AVXL), Flexion Therapeutics (FLXN) and Rigel Pharmaceuticals (RIGL).

Company Calendar

Last Earnings
5/11/2017
Today
1/22/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:EARS
Fax
N/A
Employees
132,200
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.57 per share

Miscellaneous

Free Float
N/A
Market Cap
$3.43 million
Optionable
Not Optionable
Beta
1.17
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:EARS) was last updated on 1/23/2025 by MarketBeat.com Staff
From Our Partners